Treatment options for patients with multiple myeloma who are resistant to daratumumab

Approaching a myeloma population becoming increasingly resistant to daratumumabПодробнее

Mechanisms of resistance in multiple myeloma treatmentsПодробнее

DARZALEX® IV (daratumumab) Mechanism of Action for Multiple MyelomaПодробнее

Advances in Myeloma Treatments: What Patients & Caregivers Need to KnowПодробнее

Results of Iberdomide in Combination with Dex and Daratumumab or Bortezomib in Patients with RRMMПодробнее

Rationale for Selinexor Treatment in Daratumumab-Refractory Multiple Myeloma PatientsПодробнее

New Directions in Treating Multiple Myeloma in the Era of Novel AgentsПодробнее

Targeted drug daratumumab shows promise in heavily treatment-resistant multiple myelomaПодробнее

Targeted drug daratumumab shows promise in heavily treatment-resistant multiple myelomaПодробнее

ASCO 2015: Daratumumab Shows Promise in Heavily Treatment-Resistant Multiple MyelomaПодробнее

Multiple Myeloma Treatment OptionsПодробнее

Dr. Laubach on Daratumumab as a Potential Treatment Option for Multiple MyelomaПодробнее

Everything you need to know about Daratumumab and Multiple MyelomaПодробнее

COMy 2016 Monoclonal Antibodies - Treatment of MM: LonialПодробнее

Dr. Paul Richardson on novel approaches for treating multiple myeloma | Dana-Farber Cancer InstituteПодробнее